Abu Dail Yaser, Flockerzi Elias, Munteanu Cristian, Szentmáry Nóra, Seitz Berthold, Daas Loay
Department of Ophthalmology, Saarland University Medical Center, Kirrberger Straße, Building 22, 66421 Homburg/Saar, Germany.
Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Congenital Aniridia Research, Saarland University, 66421 Homburg/Saar, Germany.
Microorganisms. 2024 Aug 30;12(9):1801. doi: 10.3390/microorganisms12091801.
Early therapeutic penetrating keratoplasty (TKP) for Acanthamoeba keratitis (AK) is thought to have a worse visual prognosis than the delayed optical penetrating keratoplasty (OKP) after successful conservative treatment of AK. This has led to a tendency to prolong conservative therapy and delay penetrating keratoplasty in patients with AK. This retrospective series presents the results of patients with AK that underwent early penetrating keratoplasty after reducing the corneal amoeba load through intensive conservative therapy, so-called "" (LLKP).
The medical records of our department were screened for patients with AK, confirmed by histological examination and/or PCR and/or in vivo confocal microscopy, which underwent ab LLKP and had a follow-up time of at least one year between 2009 and 2023. Demographic data, best corrected visual acuity (BCVA) and intraocular pressure at first and last visit, secondary glaucoma (SG), and recurrence and graft survival rates were assessed.
28 eyes of 28 patients were included. The average time from initiation of therapy to penetrating keratoplasty (PKP) was 68 ± 113 days. The mean follow-up time after LLKP was 53 ± 42 months. BCVA (logMAR) improved from 1.9 ± 1 pre-operatively to 0.5 ± 0.6 at last visit ( < 0.001). A total of 14% of patients were under medical therapy for SG at the last visit, and two of them underwent glaucoma surgery. The recurrence rate was 4%. The Kaplan-Meier graft survival rate of the first graft at four years was 70%. The second graft survival rate at four years was 87.5%.
LLKP appears to achieve a good visual prognosis with an earlier visual and psychological habilitation, as well as low recurrence and SG rates. These results should encourage us to reconsider the optimal timing of PKP in therapy-resistant AK.
对于棘阿米巴角膜炎(AK),早期治疗性穿透性角膜移植术(TKP)被认为比在AK成功保守治疗后进行的延迟性光学穿透性角膜移植术(OKP)的视力预后更差。这导致了延长保守治疗并延迟AK患者穿透性角膜移植术的趋势。本回顾性系列研究展示了通过强化保守治疗降低角膜阿米巴负荷后接受早期穿透性角膜移植术的AK患者的结果,即所谓的“低负荷角膜穿透移植术”(LLKP)。
筛选我院2009年至2023年间接受低负荷角膜穿透移植术且随访时间至少一年的AK患者的病历,这些患者经组织学检查和/或聚合酶链反应(PCR)和/或活体共聚焦显微镜检查确诊。评估人口统计学数据、首次和末次就诊时的最佳矫正视力(BCVA)和眼压、继发性青光眼(SG)以及复发率和移植物存活率。
纳入28例患者的28只眼。从开始治疗到穿透性角膜移植术(PKP)的平均时间为68±113天。低负荷角膜穿透移植术后的平均随访时间为53±42个月。BCVA(logMAR)从术前的1.9±1改善至末次就诊时的0.5±0.6(P<0.001)。末次就诊时共有14%的患者因继发性青光眼接受药物治疗,其中2例接受了青光眼手术。复发率为4%。第一次移植物4年的Kaplan-Meier存活率为70%。第二次移植物4年的存活率为87.5%。
低负荷角膜穿透移植术似乎能实现良好的视力预后,可更早实现视力和心理康复,且复发率和继发性青光眼发生率较低。这些结果应促使我们重新考虑在难治性AK中穿透性角膜移植术的最佳时机。